2122 Treatment outcomes according to extended RAS mutation testing in a phase II study of first-line mFOLFOX plus cetuximab followed by cetuximab in monotherapy as maintenance therapy or mFOLFOX plus cetuximab in patients with metastatic colorectal cancer: The MACRO-2 trial. (September 2015) - Aranda, E.; García-Alfonso, P.; Benavides, M.; Sanchez-Ruiz, A.; Guillen-Ponce, C.; Safont, M.J.; Alcaide, J.; Gomez, A.; Lopez, R.; Manzano, J.L.; Mendez-Urena, M.; Lopez, C.; et al.